Published in Virology on November 10, 1997
Membrane interactions of the tick-borne encephalitis virus fusion protein E at low pH. J Virol (2002) 1.83
Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol- and sphingolipid-containing liposomes. J Virol (1999) 1.69
Biochemical consequences of a mutation that controls the cholesterol dependence of Semliki Forest virus fusion. J Virol (2000) 1.42
Characterization of a structural intermediate of flavivirus membrane fusion. PLoS Pathog (2007) 1.37
Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS Pathog (2010) 1.35
Alphavirus Entry and Membrane Fusion. Viruses (2010) 1.31
A conserved histidine in the ij loop of the Semliki Forest virus E1 protein plays an important role in membrane fusion. J Virol (2004) 1.30
Class II fusion protein of alphaviruses drives membrane fusion through the same pathway as class I proteins. J Cell Biol (2005) 1.25
A stable prefusion intermediate of the alphavirus fusion protein reveals critical features of class II membrane fusion. Cell Host Microbe (2008) 1.11
Role of phosphatidylserine receptors in enveloped virus infection. J Virol (2014) 1.10
An epitope of the Semliki Forest virus fusion protein exposed during virus-membrane fusion. J Virol (1999) 1.10
Molecular dissection of the Semliki Forest virus homotrimer reveals two functionally distinct regions of the fusion protein. J Virol (2002) 1.02
E1 mutants identify a critical region in the trimer interface of the Semliki forest virus fusion protein. J Virol (2009) 0.97
Effects of membrane potential and sphingolipid structures on fusion of Semliki Forest virus. J Virol (2002) 0.97
Characterization of an early-stage fusion intermediate of Sindbis virus using cryoelectron microscopy. Proc Natl Acad Sci U S A (2013) 0.84
Pseudorevertants of a Semliki forest virus fusion-blocking mutation reveal a critical interchain interaction in the core trimer. J Virol (2010) 0.83
Reversible acid-induced inactivation of the membrane fusion protein of Semliki Forest virus. J Virol (2005) 0.79
Identification of a specific region in the e1 fusion protein involved in zinc inhibition of semliki forest virus fusion. J Virol (2012) 0.78
Method for measuring the unbinding energy of strongly-bound membrane-associated proteins. Biochim Biophys Acta (2016) 0.75
Fluorescence method for measuring the kinetics of fusion between biological membranes. Biochemistry (1984) 4.44
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev (1995) 3.12
Membrane fusion of Semliki Forest virus involves homotrimers of the fusion protein. J Virol (1992) 2.60
Membrane fusion of Semliki Forest virus in a model system: correlation between fusion kinetics and structural changes in the envelope glycoprotein. EMBO J (1993) 2.36
Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. J Virol (1984) 2.17
Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system. Virology (2000) 2.09
An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol (1996) 2.06
Studies on the mechanism of membrane fusion: kinetics of calcium ion induced fusion of phosphatidylserine vesicles followed by a new assay for mixing of aqueous vesicle contents. Biochemistry (1980) 2.06
Membrane fusion of Semliki Forest virus requires sphingolipids in the target membrane. EMBO J (1994) 1.99
Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek (1990) 1.97
Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin Diagn Lab Immunol (1998) 1.93
Studies on the mechanism of membrane fusion. Role of head-group composition in calcium- and magnesium-induced fusion of mixed phospholipid vesicles. Biochim Biophys Acta (1981) 1.82
Effects of low pH on influenza virus. Activation and inactivation of the membrane fusion capacity of the hemagglutinin. J Biol Chem (1987) 1.76
Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol- and sphingolipid-containing liposomes. J Virol (1999) 1.69
Fusion activity of influenza virus. A comparison between biological and artificial target membrane vesicles. J Biol Chem (1986) 1.69
SFV infection in CHO cells: cell-type specific restrictions to productive virus entry at the cell surface. J Cell Sci (1997) 1.64
Calcium/magnesium specificity in membrane fusion: kinetics of aggregation and fusion of phosphatidylserine vesicles and the role of bilayer curvature. Biochemistry (1981) 1.62
Dimethyl diotadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice. Immunology (1977) 1.51
Characterization of immunogenic properties of haptenated liposomal model membranes in mice. I. Thymus independence of the antigen. Immunology (1979) 1.47
Membrane fusion activity of influenza virus. Effects of gangliosides and negatively charged phospholipids in target liposomes. Biochemistry (1989) 1.46
Ca2+-induced fusion of phospholipid vesicles monitored by mixing of aqueous contents. Nature (1979) 1.44
Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J Immunol (1997) 1.43
Interaction of the HIV-1 fusion peptide with phospholipid vesicles: different structural requirements for fusion and leakage. Biochemistry (1994) 1.43
Kinetics of pH-dependent fusion between influenza virus and liposomes. Biochemistry (1985) 1.42
Assembly and entry mechanisms of Semliki Forest virus. Arch Virol Suppl (1994) 1.42
Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. J Gen Virol (1983) 1.40
Hydroxyurea interferes with antigen-dependent T-cell activation in vitro. Eur J Clin Invest (2000) 1.40
Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis (1995) 1.38
Characterization of the fusogenic properties of Sendai virus: kinetics of fusion with erythrocyte membranes. Biochemistry (1985) 1.37
Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis (1998) 1.35
Fusion of influenza virus in an intracellular acidic compartment measured by fluorescence dequenching. Biochim Biophys Acta (1987) 1.35
Membrane fusion activity of the influenza virus hemagglutinin: interaction of HA2 N-terminal peptides with phospholipid vesicles. Biochemistry (1991) 1.33
Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res (2008) 1.31
Evaluation of viral membrane fusion assays. Comparison of the octadecylrhodamine dequenching assay with the pyrene excimer assay. Biochemistry (1993) 1.31
Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun (1997) 1.28
Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG. Infect Immun (1994) 1.28
Membrane fusion and the lamellar-to-inverted-hexagonal phase transition in cardiolipin vesicle systems induced by divalent cations. Biophys J (1999) 1.26
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev (1993) 1.26
Fusion of Semliki Forest virus with cholesterol-containing liposomes at low pH: a specific requirement for sphingolipids. Mol Membr Biol (1995) 1.26
Calcium- and magnesium-induced fusion of mixed phosphatidylserine/phosphatidylcholine vesicles: effect of ion binding. J Membr Biol (1981) 1.24
Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine? Vaccine (2009) 1.21
Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Infect Immun (1983) 1.21
Value of the polymerase chain reaction for the detection of Toxoplasma gondii in cerebrospinal fluid from patients with AIDS. Clin Infect Dis (1993) 1.16
Delayed hypersensitivity in the mouse induced by hapten-carrier complexes. Immunology (1975) 1.15
Functional reconstitution of influenza virus envelopes. EMBO J (1987) 1.13
Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology (1998) 1.11
Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J Virol (1985) 1.11
In vitro stimulation of spleen cells of the mouse by DNP--carrier complexes. Immunology (1974) 1.11
New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun (2010) 1.10
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis (2005) 1.09
Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect Immun (1989) 1.07
Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect Immun (1996) 1.06
Physicochemical characterization of large unilamellar phospholipid vesicles prepared by reverse-phase evaporation. Biochim Biophys Acta (1983) 1.06
Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable? Clin Diagn Lab Immunol (2001) 1.05
The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virus. Immunology (1986) 1.04
Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect Immun (1991) 1.04
Role of the M2 protein in influenza virus membrane fusion: effects of amantadine and monensin on fusion kinetics. Virology (1993) 1.03
Specificity of murine delayed-type hypersensitivity to conjugates of large or small haptens on protein carriers bearing lipid groups. Immunology (1978) 1.03
X-linked genetic control of hapten-polysaccharide-mediated specific immune unresponsiveness in CBA/N mice. J Immunol (1978) 1.03
Sphingolipids activate membrane fusion of Semliki Forest virus in a stereospecific manner. Biochemistry (1995) 1.02
Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity. Int Arch Allergy Appl Immunol (1981) 1.02
Estimation of the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 by inhibition ELISA. Mol Immunol (1989) 1.02
DDA as an immunological adjuvant. Res Immunol (1992) 1.01
Preparation of a semisynthetic vaccine to Streptococcus pneumoniae type 3. Infect Immun (1983) 1.01
Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication. Clin Exp Immunol (1997) 1.00
Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants. Infect Immun (1993) 1.00
PE2 cleavage mutants of Sindbis virus: correlation between viral infectivity and pH-dependent membrane fusion activation of the spike heterodimer. J Virol (2001) 1.00
Rapid determination of neutralizing antibodies to Semliki Forest virus in serum by enzyme immunoassay in cell culture with virus-specific monoclonal antibodies. J Clin Microbiol (1986) 1.00
Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. J Gen Virol (1991) 1.00
The rate of fusion of phospholipid vesicles and the role of bilayer curvature. Biochim Biophys Acta (1982) 1.00
Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect Immun (1991) 1.00
Sphingolipid-dependent fusion of Semliki Forest virus with cholesterol-containing liposomes requires both the 3-hydroxyl group and the double bond of the sphingolipid backbone. J Virol (1995) 0.99
Modulation of membrane fusion by membrane fluidity: temperature dependence of divalent cation induced fusion of phosphatidylserine vesicles. Biochemistry (1985) 0.99
Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity. J Virol (2000) 0.99
Detection of Semliki Forest virus in cell culture by use of an enzyme immunoassay with peroxidase-labeled monoclonal antibodies specific for glycoproteins E1 and E2. J Clin Microbiol (1984) 0.99
Characterization of immunogenic properties of haptenated liposomal model membranes in mice. II. Induction of delayed-type hypersensitivity. Immunology (1981) 0.99
Membrane fusion: lipid vesicles as a model system. Chem Phys Lipids (1986) 0.98
Fusion of influenza virus with cardiolipin liposomes at low pH: mass action analysis of kinetics and extent. Biochemistry (1986) 0.98
Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther (2006) 0.97
Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur J Immunol (1998) 0.97
Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol Lett (1997) 0.97
Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect Immun (2001) 0.97
Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. Infect Immun (2001) 0.97
The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. Immunol Cell Biol (1998) 0.96
Modulation of membrane fusion by ionotropic and thermotropic phase transitions. Biochemistry (1984) 0.95
Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine (1993) 0.95
Cellular and molecular requirements for X-linked, hapten-specific B-cell blockade in CBA/N mice. J Exp Med (1978) 0.95
Studies on the mechanism of membrane fusion: role of phosphate in promoting calcium ion induced fusion of phospholipid vesicles. Biochemistry (1980) 0.95
Fusion of erythrocyte ghosts induced by calcium phosphate. Kinetic characteristics and the role of Ca2+, phosphate and calcium-phosphate complexes. Eur J Biochem (1985) 0.94
Fcgamma receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera. J Infect Dis (1999) 0.94
Fusion assays monitoring intermixing of aqueous contents. Methods Enzymol (1993) 0.94
Guanylate cyclase in Dictyostelium discoideum with the topology of mammalian adenylate cyclase. Biochem J (2001) 0.94